Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Francesca Bruce

Francesca Bruce has been writing news and analysis about all things affecting the pharmaceutical industry since 2008. She has paid special attention to policy and regulatory developments but particularly likes to write about market access and how medicines may  - or may not  -  make it to patients. She generally writes about Europe, but really enjoys uncovering news from further corners of the globe, especially Latin America and the Middle East.
Advertisement
Set Alert for Articles By Francesca Bruce

Latest From Francesca Bruce

Ibrance v Kisqali: Quicker Novartis Discount Helps Cut UK NICE’s Timeline

It took NICE, England’s health technology appraisal body, 84 days to say yes to Novartis’ Kisqali and almost a year to recommend Pfizer’s Ibrance. Willingness to sacrifice on price could have had a big impact on timelines.

Reimbursement Market Access

AstraZeneca On Bridging The Gap Between Accelerated Approval And HTA Requirements

Health technology assessment agencies are struggling to evaluate drugs on the basis of evidence generated for early approvals, says AstraZeneca.

BioPharmaceutical Approvals

Do Accelerated Approval Pathways Mean Earlier Patient Access?

Accelerated access mechanisms that aim to get medicines to the market more quickly do not necessarily mean earlier access for patients, according to interim findings from a London School of Economics study.

Europe Drug Review

EU-Mercosur Trade Deal Could See Brazilian Drug Spending Soar

Free trade talks between the EU and South American countries in the Mercosur trade bloc are set to resume on Nov. 6 in Brasilia. Critics of the EU proposals on intellectual property say they would mean Brazil spending billions more on medicines.

Europe South America

The BeNeLuxA Medicines Access Coalition: Resetting The Balance of Power in Europe?

The BeNeLuxA coalition shows that “resetting the balance of power” is possible to give governments more clout in pricing negotiations, says the European Public Health Alliance.

Europe Cost Effectiveness

Is Dutch Govt Pursuing Wider EU Discussion And Collaboration On Pricing and Reimbursement?

An initiative from the Netherlands to ensure that pharmaceutical companies market centrally approved medicines in all EU member states is probably intended to fuel discussions on the differences in national pricing and reimbursement policies, says a legal expert.

Market Access Health Technology Assessment
See All
Advertisement
UsernamePublicRestriction

Register